多发性骨髓瘤的临床与免疫表型预后因素的研究进展
| 作者: |
1徐婷婷,
1王竞飞,
1曹峰林
1 哈尔滨医科大学附属第一医院血液内科，哈尔滨 150001 |
| 通讯: |
曹峰林
Email: CFL023@163.com |
| DOI: | 10.3978/j.issn.2095-6959.2020.07.034 |
| 基金: | 国家高技术研究发展计划[(863计划)，2014AA020901]。 |
摘要
多发性骨髓瘤(multiple myeloma，MM)是一类由分泌单克隆免疫球蛋白的异常单克隆浆细胞增殖引起的B细胞恶性肿瘤疾病，临床表现为贫血、多发性骨破坏、肾功能损害等一系列临床症状。该病目前发病机制尚不明确，临床指标如C反应蛋白、乳酸脱氢酶、β2-微球蛋白等均影响MM患者的预后。免疫表型如CD56，CD28，CD200等特殊免疫表型也被确定为与预后相关。
关键词：
多发性骨髓瘤；免疫表型；预后；治疗
Research progress in clinical and immunophenotypic prognostic factors of multiple myeloma
CorrespondingAuthor: CAO Fenglin Email: CFL023@163.com
DOI: 10.3978/j.issn.2095-6959.2020.07.034
Foundation: This work was supported by the National High-Tech R&D Program, China [(863 Program), 2014AA020901].
Abstract
Multiple myeloma (MM) is a type of B cell malignant tumor caused by the proliferation of abnormal monoclonal plasma cells secreting monoclonal immunoglobulin. The clinical manifestations include anemia, multiple bone destruction, renal damage, and so on. The current pathogenesis of the disease is still unclear. Clinical indicators such as C-reactive protein, lactate dehydrogenase, β2-microglobulin, and creatinine all affect the prognosis of MM patients. Immunophenotypes such as CD56, CD28, CD200 and other specific immunophenotypes have also been identified as associated with prognosis.
Keywords：
multiple myeloma; immunophenotype; prognosis; treatment